卵巢低反应的发病机制与治疗进展  

Research progress of pathogenesis and treatment of poor ovarian response

作　　者：朱夏萱 田甜 杨蕊[1] Zhu Xiaxuan;Tian Tian;Yang Rui(Center of Reproductive Medicine,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院生殖医学中心,北京100191

出　　处：《中华生殖与避孕杂志》2023年第9期968-973,共6页Chinese Journal of Reproduction and Contraception

基　　金：北京市科技计划(Z191100006619085);国家自然科学基金(82171632);国家重点研发计划(2021YFC2700605)。

摘　　要：随着高龄产妇构成比不断增加,卵巢低反应(poor ovarian response,POR)事件发生日益增多,其所导致的体外受精周期取消率的增加和活产率的降低仍然是生殖临床医生面临的最大挑战之一。既往POR的标准混乱且异质性强,造成了临床试验和实践的不便,2016年提出的波塞冬(Patient-Oriented Strategies Encompassing Individualized Oocyte Number,POSEIDON)分类细化了患者亚群,并将概念更新为“低预后”,为规范POR标准带来了希望。随着基于POSEIDON标准的临床试验不断增加,有效治疗POR的循证医学证据不断丰富。本综述总结了当前临床试验进展,旨在为未来的POR临床诊疗提供依据。As the proportion of women with advanced maternal age increases,the incidence of poor ovarian response(POR)has been higher.Meanwhile,POR has become one of the biggest challenges for reproductive experts on account of its association with a higher cancellation rate and a lower live birth rate.Different definitions of POR population were previously used,and patient heterogeneity caused inconvenience to clinical trials and practices.In 2016,a new classification by the Patient-Oriented Strategies Encompassing Individualized Oocyte Number(POSEIDON)group was introduced,providing a more detailed stratification of the POR,and bringing forward the concept of"low prognosis"to promote more standardized strategies in these patients.Evidence-based medicine has confirmed the effectiveness of several strategies,with more and more clinical trials including POR population stratified by POSEIDON.This article reviewed newly published researches,trying to provide decision support for POR management.

关 键 词：卵巢低反应 POSEIDON 控制性卵巢刺激 促性腺激素 双重刺激方案 

分 类 号：R711.75[医药卫生—妇产科学]